Johnson & Johnson (NYSE:JNJ) Shares Bought by Monograph Wealth Advisors LLC

Monograph Wealth Advisors LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 8.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,458 shares of the company’s stock after acquiring an additional 359 shares during the quarter. Monograph Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $645,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Tallon Kerry Patrick acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $290,000. Capital & Planning LLC increased its holdings in Johnson & Johnson by 13.6% during the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock valued at $221,000 after acquiring an additional 183 shares in the last quarter. Taylor & Morgan Wealth Management LLC raised its position in Johnson & Johnson by 29.4% during the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 4,572 shares of the company’s stock worth $661,000 after acquiring an additional 1,038 shares during the last quarter. Kera Capital Partners Inc. purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $351,000. Finally, Monarch Capital Management Inc. grew its position in shares of Johnson & Johnson by 1.3% in the fourth quarter. Monarch Capital Management Inc. now owns 60,264 shares of the company’s stock valued at $8,715,000 after purchasing an additional 790 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent research reports. Stifel Nicolaus reduced their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Raymond James reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research report on Monday, April 14th. Wells Fargo & Company dropped their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, Benchmark raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $153.58 on Wednesday. The stock’s 50-day moving average is $155.87 and its 200-day moving average is $153.80. The company has a market cap of $369.52 billion, a price-to-earnings ratio of 23.09, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.39%. Johnson & Johnson’s dividend payout ratio is 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.